Do you want to read an article? Please log in or register.
Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis
Related content
Pulmonary Fibrosis
The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicenter observational study
Eur Respir J.
Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C
doi: 10.1183/13993003.
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Tomassetti S, Ravaglia C, Wells AU, Cavazza A, Colby TV, Rossi G, Ley B, Ryu JH, Puglisi S, Arcadu A, Marchi M, Sultani F, Martinello S, Donati L, Gurioli C, Gurioli C, Tantalocco P, Hetzel J, Dubini A, Piciucchi S, Klersy C, Lavorini F, Poletti V
doi: 10.1016/S2213-2600(20)30122-3.
RECOMMENDED
Pulmonary Fibrosis
Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir Rev.
Caminati A, Lonati C, Cassandro R, Elia D, Pelosi G, Torre O, Zompatori M, Uslenghi E, Harari S
doi: 10.1183/16000617.0044-2019.
COMMENTED
Pulmonary Fibrosis
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
Lancet Respir Med.
Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR
doi: 10.1016/
RECOMMENDED
Pulmonary Fibrosis
Short-Term Effects of Comprehensive Pulmonary Rehabilitation and its Maintenance in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Controlled Trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med.
Jarosch I, Schneeberger T, Gloeckl R, Kreuter M, Frankenberger M, Neurohr C, Prasse A, Freise J, Behr J, Hitzl W, Koczulla AR, Kenn K
doi: 10.3390/jcm9051567.
Pulmonary Fibrosis
Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review
Respir Res.
Hayton C, Terrington D, Wilson AM, Chaudhuri N, Leonard C, Fowler SJ
doi: 10.1186/s12931-019-0971-8.
RECOMMENDED
Pulmonary Fibrosis
Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA, IPF-PRO™ Registry investigators.
doi: 10.1016/j.chest.2019.12.041.
Pulmonary Fibrosis
Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study
Lancet Respir Med.
Herazo-Maya JD, Sun J, Molyneaux PL, Li Q, Villalba JA, Tzouvelekis A, Lynn H, Juan-Guardela BM, Risquez C, Osorio JC, Yan X, Michel G, Aurelien N, Lindell KO, Klesen MJ, Moffatt MF, Cookson WO, Zhang Y, Garcia JGN, Noth I, Prasse A, Bar-Joseph Z, Gibson KF, Zhao H, Herzog EL, Rosas IO, Maher TM, Kaminski N
doi: 10.1016/
RECOMMENDED
Pulmonary Fibrosis
Clinical Effectiveness of the Anti-Fibrotic Medications for Idiopathic Pulmonary Fibrosis
Am J Respir Crit Care Med.
Dempsey TM, Sangaralingham LR, Yao X, Sanghavi D, Shah ND, Limper AH
doi: 10.1164/rccm.